An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 272 participants.

Also called NCT01064414

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 272 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01064414
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Brazil, Canada, France, Germany, India, Latvia, Malaysia, Mexico, New Zealand, Poland, Romania, Russia, South Africa, South Korea, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01064414. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2013-05-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Condition
Diabetes Mellitus, Type 2
Condition
Renal Insufficiency
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01064414
Content hash
2974a5172b238b16ae4aa032a24a4f34135e20a92cbe63b3857f783afbbeb756